BTIG raised the firm's price target on Spectral AI to $4 from $3 and keeps a Buy rating on the shares after the company announced it received FDA clearance for the DeepView System for Burn Centers, Trauma Centers, and Emergency Departments. FDA clearance is a significant milestone for the company as the DeepView System has been in development and clinical investigation for numerous years, the analyst tells investors in a research note.
